Oncology Vol 29 No 1

Chemotherapy for Soft-Tissue Sarcomas

January 15, 2015

In patients with high-risk localized disease, the use of systemic chemotherapy should be strongly considered to delay recurrence and/or reduce the patient’s risk of developing metastatic disease. In patients with metastatic disease, systemic chemotherapy remains the mainstay of treatment.

Osteoclast Inhibitors: A Multifaceted Tool in the Management of Breast Cancer

January 15, 2015

There are still questions to be answered about the use of osteoclast inhibitors in the care of patients with breast cancer. The optimal duration and dosing schedule and how to improve treatment compliance are important issues to address.

The Double-Edged Sword of ADT: Emerging Evidence of Cardiovascular, Pulmonary, and Renal Risks

January 15, 2015

As a variety of new hormonal agents are increasing survival times for men with metastatic disease, it is becoming increasingly important to consider cardiovascular, renal, and other potentially more serious risks associated with long-term ADT, especially in an aging population.

Chemotherapy in Soft-Tissue Sarcoma: Where Do We Go From Here?

January 15, 2015

While the future is bright for the development and investigation of novel chemotherapeutics for treatment of soft-tissue sarcoma, investigators will need to gain better insight into the molecular drivers of pathogenesis, and give continued thoughtful consideration to clinical trial design.

Bisphosphonates in Breast Cancer: A Triple Winner?

January 15, 2015

We know that bisphosphonates prevent or delay skeletal-related events in breast cancer metastatic to bone, prevent or treat bone loss in patients receiving adjuvant aromatase inhibitor therapy, and decrease bone recurrences and breast cancer–related deaths when used in the adjuvant setting in postmenopausal women with early-stage breast cancer.

Big Data: Not Really the Same as Level 1 Data

January 15, 2015

The problem with large sets of data is the risk of the “GIGO” principle-viz. garbage in, garbage out-and it requires a very careful and thoughtful investigator to rule out the many errors of large-scale data capture.

ADT Risks and Side Effects in Advanced Prostate Cancer: Cardiovascular and Acute Renal Injury

January 15, 2015

This article reviews recent evidence suggesting an increased risk of pneumonia, cardiovascular disease, and acute kidney injury in men treated with ADT and consider whether the incidence of such events differs with the treatment modality.